Patrick Burnett has sold ARQT and made no open-market buys since Mar 2023

Patrick E. Burnett is an accomplished medical executive serving as Chief Medical Officer (CMO) and Executive Vice President at Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), a biopharmaceutical company focused on dermatology treatments.( He joined Arcutis in August 2020 and has been instrumental in the company's clinical development efforts, including recent FDA approvals for products like ZORYVE foam for plaque psoriasis.( As of late 2025, Dr. Burnett, aged 52, owns approximately 98,325 shares of ARQT stock valued at over $2.9 million, with an annual salary of $722,940.( He has engaged in recent insider trading, including selling 17,250 shares on November 6, 2025, for $417,105, and earlier transactions under a 10b5-1 plan totaling around $432,700 in July 2025.(

Prior to Arcutis, Dr. Burnett served as Chief Medical Officer at Verrica Pharmaceuticals, bringing extensive expertise in pharmaceutical development.( His career highlights include leadership in clinical programs for dermatological and other therapies, positioning him among key executives at ARcutis, where he reports to CEO Todd Watanabe.( Detailed education and early career information are not specified in available sources.

Written by Perplexity from public sources.